论文部分内容阅读
目的探讨肿瘤表观扩散系数(ADC)值对Her-2过表达型乳腺癌新辅助化疗(NAC)疗效早期评估的价值。方法回顾性分析36例经NAC治疗的Her-2过表达型乳腺癌患者资料,分别测量患者行NAC前及1周期后肿瘤ADC值,观察ADC值的变化。以术后病理结果为金标准,通过ROC观察ADC值早期判断Her-2过表达型乳腺癌NAC的敏感度和特异度,并确定评估其化疗疗效的ADC值界点。结果乳腺癌NAC有效21例,无效15例。△ADC曲线下面积0.968,具有较好的诊断效果;当△ADC值>0.08时,评价疗效的敏感度81%,特异度100%。结论通过ADC值早期判断Her-2过表达型乳腺癌NAC疗效具有可行性,敏感度和特异度均较高。对于临床治疗方案的实施具有一定的参考价值。
Objective To investigate the value of tumor apparent diffusion coefficient (ADC) value in the early evaluation of the efficacy of neoadjuvant chemotherapy (NAC) for Her-2 overexpression breast cancer. Methods The data of 36 patients with NAC-overexpressing Her-2 overexpression breast cancer were retrospectively analyzed. The ADC value of tumor before and after NAC was measured and the change of ADC value was observed. The postoperative pathological results were taken as the gold standard. The sensitivity and specificity of ROC for the early diagnosis of NAC in Her-2 overexpression breast cancer were determined by ROC. The ADC value of the response to chemotherapy was determined. Results Breast cancer NAC effective in 21 cases, 15 cases were ineffective. △ ADC curve under the area of 0.968, with good diagnostic results; when △ ADC value> 0.08, the evaluation of the efficacy of the sensitivity of 81%, 100% specificity. Conclusion The early diagnosis of NAC with Her-2 overexpression breast cancer by ADC value is feasible and the sensitivity and specificity are high. For the clinical treatment program has a certain reference value.